These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 21456887)
21. Effect of bisphosphonates on bone mineral density and fracture prevention in gastric cancer patients after gastrectomy. Lim JS; Jin SH; Kim SB; Lee JI J Clin Gastroenterol; 2012 Sep; 46(8):669-74. PubMed ID: 22504799 [TBL] [Abstract][Full Text] [Related]
22. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. Black DM; Kelly MP; Genant HK; Palermo L; Eastell R; Bucci-Rechtweg C; Cauley J; Leung PC; Boonen S; Santora A; de Papp A; Bauer DC; ; N Engl J Med; 2010 May; 362(19):1761-71. PubMed ID: 20335571 [TBL] [Abstract][Full Text] [Related]
23. Effect of bisphosphonate on hip fracture in patients with osteoporosis or osteopenia according to age: a meta-analysis and systematic review. Zhao S; Zhao W; Du D; Zhang C; Zhao T; Zheng L; Jin L; Gu M; Xu J; Yang Z J Investig Med; 2022 Mar; 70(3):837-843. PubMed ID: 34893517 [TBL] [Abstract][Full Text] [Related]
24. The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis. Jansen JP; Bergman GJ; Huels J; Olson M Semin Arthritis Rheum; 2011 Feb; 40(4):275-84.e1-2. PubMed ID: 20828791 [TBL] [Abstract][Full Text] [Related]
25. The impact of fewer hip fractures with risedronate versus alendronate in the first year of treatment: modeled German cost-effectiveness analysis. Thompson M; Pasquale M; Grima D; Moehrke W; Kruse HP Value Health; 2010; 13(1):46-54. PubMed ID: 19883401 [TBL] [Abstract][Full Text] [Related]
26. Sunlight exposure is important for preventing hip fractures in patients with Alzheimer's disease, Parkinson's disease, or stroke. Iwamoto J; Takeda T; Matsumoto H Acta Neurol Scand; 2012 Apr; 125(4):279-84. PubMed ID: 21682695 [TBL] [Abstract][Full Text] [Related]
27. Atypical femur fractures among breast cancer and multiple myeloma patients receiving intravenous bisphosphonate therapy. Chang ST; Tenforde AS; Grimsrud CD; O'Ryan FS; Gonzalez JR; Baer DM; Chandra M; Lo JC Bone; 2012 Sep; 51(3):524-7. PubMed ID: 22634175 [TBL] [Abstract][Full Text] [Related]
28. Bisphosphonates and atrial fibrillation: systematic review and meta-analysis. Loke YK; Jeevanantham V; Singh S Drug Saf; 2009; 32(3):219-28. PubMed ID: 19338379 [TBL] [Abstract][Full Text] [Related]
29. Pharmacovigilance of oral bisphosphonates: adverse effects manifesting in the soft tissue of the oral cavity. Kharazmi M; Persson U; Warfvinge G J Oral Maxillofac Surg; 2012 Dec; 70(12):2793-7. PubMed ID: 22609135 [TBL] [Abstract][Full Text] [Related]
30. Bisphosphonates and risk of cardiovascular events: a meta-analysis. Kim DH; Rogers JR; Fulchino LA; Kim CA; Solomon DH; Kim SC PLoS One; 2015; 10(4):e0122646. PubMed ID: 25884398 [TBL] [Abstract][Full Text] [Related]
33. Meta-analysis: oral bisphosphonates and the risk of oesophageal cancer. Andrici J; Tio M; Eslick GD Aliment Pharmacol Ther; 2012 Oct; 36(8):708-16. PubMed ID: 22966908 [TBL] [Abstract][Full Text] [Related]
34. Oral Treatment With Bisphosphonates of Osteoporosis Does Not Increase the Risk of Severe Gastrointestinal Side Effects: A Meta-Analysis of Randomized Controlled Trials. Dömötör ZR; Vörhendi N; Hanák L; Hegyi P; Kiss S; Csiki E; Szakó L; Párniczky A; Erőss B Front Endocrinol (Lausanne); 2020; 11():573976. PubMed ID: 33240217 [TBL] [Abstract][Full Text] [Related]
35. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies. Cosman F; Borges JL; Curiel MD Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726 [TBL] [Abstract][Full Text] [Related]
36. Oral bisphosphonate use and total knee/hip implant survival: validation of results in an external population-based cohort. Prieto-Alhambra D; Lalmohamed A; Abrahamsen B; Arden NK; de Boer A; Vestergaard P; de Vries F Arthritis Rheumatol; 2014 Nov; 66(11):3233-40. PubMed ID: 25047677 [TBL] [Abstract][Full Text] [Related]
37. Bone Loss Prevention of Bisphosphonates in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Hu Y; Chen X; Chen X; Zhang S; Jiang T; Chang J; Gao Y Can J Gastroenterol Hepatol; 2017; 2017():2736547. PubMed ID: 28913325 [TBL] [Abstract][Full Text] [Related]
38. The use of bisphosphonate in the treatment of osteonecrosis of the femoral head: a meta-analysis of randomized control trials. Yuan HF; Guo CA; Yan ZQ Osteoporos Int; 2016 Jan; 27(1):295-9. PubMed ID: 26370828 [TBL] [Abstract][Full Text] [Related]
39. Bisphosphonate Use After Hip Fracture in Older Adults: A Nationwide Retrospective Cohort Study. Nordström P; Toots A; Gustafson Y; Thorngren KG; Hommel A; Nordström A J Am Med Dir Assoc; 2017 Jun; 18(6):515-521. PubMed ID: 28238673 [TBL] [Abstract][Full Text] [Related]
40. Oral bisphosphonate use and age-related macular degeneration: retrospective cohort and nested case-control study. Garriga C; Pazianas M; Hawley S; Delmestri A; Prieto-Alhambra D; Cooper C; Judge A Ann N Y Acad Sci; 2018 Mar; 1415(1):34-46. PubMed ID: 29363763 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]